Medtronic PLC
- Industry
- Medical Devices
- Exchange
- US
- Country
- USA
- IPO date
- Jan 13, 1978
- Employees
- 95,000
- Website
- www.medtronic.com
Composite valuation range · conservative $50–$60 / fair $60–$80 / optimistic $80–$100. At $84.22, Within the optimistic intrinsic-value range · much expectation priced in.
At publication $78 (May 25, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys
History
Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland, with its IPO dated January 13, 1978. A defining transaction was its 2015 acquisition of Covidien for about USD 50 billion, which expanded its technology portfolio and global scale. The company has built more than 70 years of brand history. It has also reshaped its business mix through divestitures, including selling its non-core renal care business.
Industry position
Medtronic is one of the global leaders in medical devices, ranking second worldwide by sales in 2023, and holds roughly a 50% share in cardiac pacemakers and rhythm-management devices. It operates four reporting segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes; in fiscal 2023 revenue of about USD 31.23 billion split into Cardiovascular USD 11.57 billion (37.1%), Neuroscience USD 9.83 billion (31.5%), Medical Surgical USD 7.62 billion (24.0%), and Diabetes USD 2.20 billion (7.1%). It employs about 95,000 people, with fiscal 2025 R&D spending of about USD 2.732 billion (~8.1% of revenue). Key competitors include Abbott, Johnson & Johnson, Boston Scientific, Stryker, and Edwards Lifesciences.